Pharmafile Logo
Pharmafocus logo
Advanced Search

Skyrizi

Showing 4 posts of 4 posts found.

abbvie_0

AbbVie’s Skyrizi outpaces Novartis’ Cosentyx in plaque psoriasis skin clearance

January 16, 2020
Research and Development AbbVie, Cosentyx, Novartis, Skyrizi, pharma, psoriasis

AbbVie has made it known that Skyrizi (risankizumab) outpaced Novartis’ Cosentyx (secukinumab) at Phase 3 in the treatment of plaque …

News

NHS patients to receive AbbVie’s Skyrizi for plaque psoriasis following NICE recommendation

August 21, 2019
Research and Development, Sales and Marketing AbbVie, NICE, Skyrizi, pharma

AbbVie’s Skyrizi (risankizumab) has been awarded a positive recommendation from UK drug watchdog NICE, meaning that the IL-23 inhibitor will …

News
abbvie_0

AbbVie’s Skyrizi snatches up FDA approval in moderate to severe plaque psoriasis

April 24, 2019
Research and Development, Sales and Marketing AbbVie, FDA, Skyrizi, US, pharma, psoriasis

AbbVie has revealed that its interleukin-23 (IL-23) inhibitor Skyrizi (risankizumab-rzaa) has received marketing authorisation in the US from the FDA …

News
abbvie_0

Japan awards AbbVie’s Skyrizi with first approval, in 4 psoriasis indications

March 27, 2019
Research and Development, Sales and Marketing AbbVie, Japan, Skyrizi, pharma, psoriasis

AbbVie has announced that its interleukin-23 (IL-23) inhibitor Skyrizi (risankizumab) has been awarded approval in Japan from the nation’s Ministry …

News

Latest content

Ardena announces €20m expansion following first GMP approval

April 19, 2024

Roche’s Alecensa approved by FDA as lung cancer treatment

April 19, 2024

GSK shares results from phase 3 trial for gonorrhoea treatment

April 18, 2024

Eli Lilly’s tirzepatide demonstrates efficacy in reducing sleep apnoea severity

April 18, 2024

Medincell and AbbVie enter agreement for development of next-generation injectables

April 17, 2024